About Glut1 DS In Focus
Glut1 DS In Focus is a program devoted to educating patients, caregivers, and doctors about Glut1 DS. We aim to bring the Glut1 DS community the most up-to-date information about the disease, diagnosis, treatment advances, and clinical study opportunities, and to emphasize the importance of genetic testing.
The mission of Glut1 DS In Focus is to provide a trusted, educational, and informational resource for patients, caregivers, and doctors. We strive to lead the Glut1 DS community in both understanding the disease and looking ahead toward a treatment that redefines the long-term prognosis.
Glut1 DS In Focus is sponsored by Ultragenyx Pharmaceutical Inc. Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company dedicated to bringing to market novel products for the treatment of rare and ultrarare diseases, with a focus on serious, debilitating genetic diseases. There are more than 7000 rare and ultrarare diseases in the world, with treatments (or treatment options) for only 400 of them.
The goal of Ultragenyx is to help people with rare diseases and unmet medical needs by working closely with patients, families, doctors, and patient organizations to understand how these diseases affect people’s lives, the advantages and disadvantages of any current treatments, and the hopes for potential new treatment options. Today, Ultragenyx is developing 4 potential treatments for 6 rare diseases. Glut1 DS is one of these diseases.
Visit the website to learn more.